What is the economic burden of delayed axial spondyloarthritis diagnosis in the UK?
Delayed axial SpA diagnosis carries high costs for society due to productivity losses. Early diagnosis and treatment could offer significant benefits to the patient and potentially reduce productivity losses; however, future research is needed to evaluate the long-term health economic impact.
Authors
- Stephanie Howard Wilsher (ORCID: https://orcid.org/0000-0002-3060-3270)
- Oyewumi Afolabi (ORCID: https://orcid.org/0000-0002-1008-8507)
- Richard Fordham (ORCID: https://orcid.org/0000-0002-5520-6255)
- Joe Eddison
- Jill B. Hamilton (ORCID: https://orcid.org/0000-0002-6553-5079)
- Karl Gaffney (ORCID: https://orcid.org/0000-0002-7863-9176)
- Raj Sengupta (ORCID: https://orcid.org/0000-0002-9720-0396)
- Thomas A Ingram (ORCID: https://orcid.org/0000-0003-2319-9342)
- Fernando Zanghelini (ORCID: https://orcid.org/0000-0002-4913-9498)
- George J. Xydopoulos (ORCID: https://orcid.org/0000-0003-4561-1238)
- Colin Clark (ORCID: https://orcid.org/0000-0002-6028-5197)
- Dale Webb
Institutions
- University of East Anglia (GB)
- Royal National Hospital for Rheumatic Diseases (GB)
- Norwich University (US)
- Norfolk and Norwich University Hospitals NHS Foundation Trust (GB)
- Arthritis Society (CA)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1093/rheumatology/keaf226
- Citations
- 2
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Biogen
- National Institute for Health and Care Excellence
- Celltrion
- Versus Arthritis
- UCB Pharma